Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis.

Swanson, Linnea A; Kassab, Ihab; Tsung, Irene; Schneider, Bryan J; Fontana, Robert J

Swanson, Linnea A; Kassab, Ihab; Tsung, Irene; Schneider, Bryan J; Fontana, Robert J.

Afiliação

Swanson LA; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
Kassab I; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
Tsung I; Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States.
Schneider BJ; Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States.
Fontana RJ; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, United States.

Front Oncol ; 12: 984940, 2022.

Article em En | MEDLINE | ID: mdl-36353563

Palavras-chave

Roussel Uclaf Causality Assessment Method; biliary tract cancer; checkpoint inhibitors; drug hepatotoxicity; drug induced liver injury; immune-mediated liver injury; immunotherapy; lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google